202 related articles for article (PubMed ID: 23216269)
1. Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.
Monaghan SA; Dai L; Mapara MY; Normolle DP; Gollin SM; Lentzsch S
Leuk Lymphoma; 2013 Sep; 54(9):1965-74. PubMed ID: 23216269
[TBL] [Abstract][Full Text] [Related]
2. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
Kotchetkov R; Masih-Khan E; Chu CM; Atenafu EG; Chen C; Kukreti V; Trudel S; Tiedemann R; Reece DE
Cancer Med; 2017 Jan; 6(1):3-11. PubMed ID: 27860411
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group.
Usnarska-Zubkiewicz L; Dębski J; Butrym A; Legieć W; Hus M; Dmoszyńska A; Stella-Hołowiecka B; Zaucha JM; Januszczyk J; Rymko M; Torosian T; Charliński G; Lech-Marańda E; Malenda A; Jurczyszyn A; Urbańska-Ryś H; Druzd-Sitek A; Błońska D; Urbanowicz A; Hołojda J; Pogrzeba J; Rzepecki P; Hałka J; Subocz E; Becht R; Zdziarska B; Dytfeld D; Nowicki A; Bołkun Ł; Kłoczko J; Knopińska-Posłuszny W; Zubkiewicz-Kucharska A; Kuliczkowski K
Leuk Res; 2016 Jan; 40():90-9. PubMed ID: 26626207
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.
Zhou DB; Yu L; Du X; Jin J; Cai Z; Chen F; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; DeMarco D; Chen N; Mei J; Wang J; Hou J
Int J Hematol; 2015 Jun; 101(6):569-77. PubMed ID: 25753225
[TBL] [Abstract][Full Text] [Related]
5. Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.
Gertz MA; Terpos E; Dispenzieri A; Kumar S; Shah RA; Orlowski R; Kastritis E; Dimopoulos MA; Shah J
Leuk Lymphoma; 2015 Jun; 56(6):1723-6. PubMed ID: 25284489
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide in myelodysplastic syndrome and multiple myeloma.
Shah SR; Tran TM
Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide.
Montefusco V; Galli M; Spina F; Stefanoni P; Mussetti A; Perrone G; De Philippis C; Dalto S; Maura F; Bonini C; Rezzonico F; Pennisi M; Roncari L; Soldarini M; Dodero A; Farina L; Cocito F; Caprioli C; Corradini P
Leuk Lymphoma; 2014 Sep; 55(9):2032-7. PubMed ID: 24730540
[TBL] [Abstract][Full Text] [Related]
8. B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.
Sinit RB; Hwang DG; Vishnu P; Peterson JF; Aboulafia DM
BMC Cancer; 2019 Nov; 19(1):1147. PubMed ID: 31775673
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Syed YY
Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
Badros A; Morris C; Zangari M; Barlogie B; Tricot G
Leuk Lymphoma; 2002 Jun; 43(6):1267-71. PubMed ID: 12152995
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
Matarraz S; Paiva B; Diez-Campelo M; López-Corral L; Pérez E; Mateos MV; Giraldo P; Hernández MT; San Miguel JF; Orfao A;
Haematologica; 2012 Oct; 97(10):1608-11. PubMed ID: 22511492
[TBL] [Abstract][Full Text] [Related]
13. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
[No Abstract] [Full Text] [Related]
14. The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.
Brioli A; Melchor L; Titley I; Vijayaraghavan G; Stephens C; Zeisig A; Pawlyn C; Cavo M; Morilla R; Davies FE; Morgan GJ
Leuk Lymphoma; 2014 Nov; 55(11):2665-8. PubMed ID: 24660850
[No Abstract] [Full Text] [Related]
15. Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
Nakamura N; Kanemura N; Shibata Y; Matsumoto T; Mabuchi R; Nakamura H; Kitagawa J; Goto N; Hara T; Tsurumi H; Moriwaki H
Leuk Lymphoma; 2014 Jul; 55(7):1691-3. PubMed ID: 24138307
[No Abstract] [Full Text] [Related]
16. An update on the use of lenalidomide for the treatment of multiple myeloma.
Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Pharmacother; 2015; 16(12):1865-77. PubMed ID: 26165832
[TBL] [Abstract][Full Text] [Related]
17. New immunomodulatory drugs in myeloma.
Lacy MQ
Curr Hematol Malig Rep; 2011 Jun; 6(2):120-5. PubMed ID: 21327565
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
Arcioni F; Roncadori A; Di Battista V; Tura S; Covezzoli A; Cundari S; Mecucci C;
Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
Gay F; Hayman SR; Lacy MQ; Buadi F; Gertz MA; Kumar S; Dispenzieri A; Mikhael JR; Bergsagel PL; Dingli D; Reeder CB; Lust JA; Russell SJ; Roy V; Zeldenrust SR; Witzig TE; Fonseca R; Kyle RA; Greipp PR; Stewart AK; Rajkumar SV
Blood; 2010 Feb; 115(7):1343-50. PubMed ID: 20008302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]